2026年5月5日，玮俊生物科技有限公司（00660）发布公告，披露通过转换金额为1,350,000港元的可换股债券，以每股0.01港元的价格发行22,500,000股新股。该批新增股份占转换前公司已发行股份（345,143,119股）的约6.52%。
本次发行完成后，公司已发行股本由345,143,119股增至367,643,119股，库藏股数量保持为0。公司声明已按所有适用的上市规则及相关法律规定办理本次股份发行事宜。
公告由董事林家俊签署。
2026年5月5日，玮俊生物科技有限公司（00660）发布公告，披露通过转换金额为1,350,000港元的可换股债券，以每股0.01港元的价格发行22,500,000股新股。该批新增股份占转换前公司已发行股份（345,143,119股）的约6.52%。
本次发行完成后，公司已发行股本由345,143,119股增至367,643,119股，库藏股数量保持为0。公司声明已按所有适用的上市规则及相关法律规定办理本次股份发行事宜。
公告由董事林家俊签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.